# C_2018170EN.01001201.xml

| 17.5.2018 | EN | Official Journal of the European Union | C 170/12 |
| --- | --- | --- | --- |

17.5.2018

EN

Official Journal of the European Union

C 170/12

---

Prior notification of a concentration

(Case M.8887 — Platinum Equity/LifeScan)

Candidate case for simplified procedure

(Text with EEA relevance)

(2018/C 170/09)

| 1. | On 4 May 2018, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
  This notification concerns the following undertakings:






  — | Platinum Equity (‘Platinum’, United States), |
| --- | --- | --- |

1.

On 4 May 2018, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

1

This notification concerns the following undertakings:

—

Platinum Equity (‘Platinum’, United States),

| — | LifeScan, Inc., part of Johnson&Johnson (United States). |
| --- | --- |

—

LifeScan, Inc., part of Johnson&Johnson (United States).

The proposed concentration consists of the acquisition by Platinum of the LifeScan blood glucose monitoring business. Platinum will acquire sole control of LifeScan within the meaning of Article 3(1)(b) of the Merger Regulation.

The concentration is accomplished by way of purchase of shares and assets through a special purpose vehicle.

| 2. | The business activities of the undertakings concerned are:
  —   for Platinum: a private investment firm, specialised in the merger, acquisition and operation of companies in a broad range of businesses, including information technology, telecommunications, logistics, metal services, manufacturing and distribution at global level,
  —   for LifeScan: provides blood glucose monitoring systems for home and hospital use under the global brand OneTouch. The OneTouch portfolio includes personal blood glucose meters, testing strips, lancets, point of care testing systems and integrated digital solutions. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   for Platinum: a private investment firm, specialised in the merger, acquisition and operation of companies in a broad range of businesses, including information technology, telecommunications, logistics, metal services, manufacturing and distribution at global level,

for Platinum

—   for LifeScan: provides blood glucose monitoring systems for home and hospital use under the global brand OneTouch. The OneTouch portfolio includes personal blood glucose meters, testing strips, lancets, point of care testing systems and integrated digital solutions.

for LifeScan

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
  Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
  M.8887 — Platinum Equity/LifeScan
  Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:





  Email: COMP-MERGER-REGISTRY@ec.europa.eu |
| --- | --- |
| Fax +32 22964301 |
| Postal address: |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.8887 — Platinum Equity/LifeScan

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---